Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 27)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 New Constructs, LLC N/A KERX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala KERYX BIOPHARMACEUTICALS INC (KERX=US) 12-months forecast 1 $15 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: KERYX BIOPHARM -- KERX 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ADLR , BIOD , INFI , JAV , KERX , MBRK , NGSX , SNTA -- DRUGS 3 $4 View Abstract
1-Feb-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD KERX: Keryx Reports Positive Phase 2 Results in Waldenstrom’s Macroglobulinemia 4 $10 View Abstract
31-Jan-10 Wright Reports N/A Wright Investors Service Comprehensive Report for Keryx Biopharmaceuticals, Inc. 44 $65 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: KERYX BIOPHARMACEUTICALS INC 5 $25 View Abstract
26-Jan-10 Zacks Investment Research Inc. N/A KERYX BIOPHARMA (KERX) Zacks Company Snapshot 1 $10 View Abstract
Next 17

Brokerage Reports (Showing 1 to 3 of 3)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
1-Feb-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD KERX: Keryx Reports Positive Phase 2 Results in Waldenstrom’s Macroglobulinemia 4 $10 View Abstract
25-Jan-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD KERX: Reports Positive Updated Perifosine Data in Refractory Colorectal Cancer 5 $10 View Abstract
5-Jan-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD KERX: Keryx Receives Zerenex SPA – Has Sufficient Capital to Conduct Phase 3 Trials for Both Zerenex and Perifosine 4 $10 View Abstract

Independent Reports (Showing 1 to 10 of 24)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 New Constructs, LLC N/A KERX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala KERYX BIOPHARMACEUTICALS INC (KERX=US) 12-months forecast 1 $15 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: KERYX BIOPHARM -- KERX 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ADLR , BIOD , INFI , JAV , KERX , MBRK , NGSX , SNTA -- DRUGS 3 $4 View Abstract
31-Jan-10 Wright Reports N/A Wright Investors Service Comprehensive Report for Keryx Biopharmaceuticals, Inc. 44 $65 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: KERYX BIOPHARMACEUTICALS INC 5 $25 View Abstract
26-Jan-10 Zacks Investment Research Inc. N/A KERYX BIOPHARMA (KERX) Zacks Company Snapshot 1 $10 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: KERYX BIOPHARMACEUTICALS INC 5 $25 View Abstract
Next 14

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.